Evidence map›Paper›PMID 37047470›Full record

ArticleInternational journal of molecular sciences2023

Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II.

Jiayan Huang, Ezgi Caliskan Guzelce, Shadi K Gholami, Kara L Gawelek, Richard N Mitchell, Luminita H Pojoga, Jose R Romero, Gordon H Williams, Gail K Adler

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiayan HuangDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1649-1428
Ezgi Caliskan GuzelceDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9574-8032
Shadi K GholamiDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-1429-118X
Kara L GawelekDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Richard N MitchellDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Luminita H PojogaDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jose R RomeroDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Gordon H WilliamsDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Gail K AdlerDivision of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Brigham and Women's Hospital · US

Funding

TRAINING PROGRAM IN HYPERTENSIONT32HL007609 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 1985 to 2022
$10.2M
Regulation of Aldosterone: The Effect of StatinsR01HL136567 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 2017 to 2020
$3.4M
Aldosterone and Diabetic Cardiovascular Disease: Research and Mentoring ProgamK24HL103845 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 2011 to 2021
$1.6M
National Institute of Health National Heart, Lung, and Blood K24HL103845National Institute of Health National Heart, Lung, and Blood R01HL136567National Institute of Health National Heart, Lung, and Blood T32HL007609National Institute of Health National Heart, Lung, and Blood Institute R01HL11476NHLBI NIH HHS K24 HL103845NHLBI NIH HHS R01 HL136567NHLBI NIH HHS T32 HL007609
6 · The paper itself

Abstract

Kidney injury molecule-1 (KIM-1) is a biomarker of renal injury and a predictor of cardiovascular disease. Aldosterone, via activation of the mineralocorticoid receptor, is linked to cardiac and renal injury. However, the impact of mineralocorticoid receptor activation and blockade on KIM-1 is uncertain. We investigated whether renal KIM-1 is increased in a cardiorenal injury model induced by L-NAME/ANG II, and whether mineralocorticoid receptor blockade prevents the increase in KIM-1. Since statin use is associated with lower aldosterone, we also investigated whether administering eiSther a lipophilic statin (simvastatin) or a hydrophilic statin (pravastatin) prevents the increase in renal KIM-1. Female Wistar rats (8-10 week old), consuming a high salt diet (1.6% Na+), were randomized to the following conditions for 14 days: control; L-NAME (0.2 mg/mL in drinking water)/ANG II (225 ug/kg/day on days 12-14); L-NAME/ANG II + eplerenone (100 mg/kg/day p.o.); L-NAME/ANG II + pravastatin (20 mg/kg/day p.o.); L-NAME/ANG II + simvastatin (20 mg/kg/day p.o.). Groups treated with L-NAME/ANG II had significantly higher blood pressure, plasma and urine aldosterone, cardiac injury/stroke composite score, and renal KIM-1 than the control group. Both eplerenone and simvastatin reduced 24-h urinary KIM-1 (

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionStrokeAldosteroneAngiotensin IIAnimalsBlood PressureEplerenoneFemaleHepatitis A Virus Cellular Receptor 1KidneyNG-Nitroarginine Methyl EsterPravastatinRatsRats, WistarReceptors, MineralocorticoidAldosteroneAngiotensin IIEplerenoneHepatitis A Virus Cellular Receptor 1Hydroxymethylglutaryl-CoA Reductase InhibitorsNG-Nitroarginine Methyl EsterPravastatinReceptors, MineralocorticoidRNA, MessengerSimvastatinangiotensin II (ANG II)CVD (cardiovascular disease)kidney injury molecule (KIM-1)mineralocorticoid receptor (MR)N-omega-nitro-L-arginine methyl ester (L-NAME)pravastatinsimvastatinstatin

Identifiers

PMID37047470
PMCPMC10095483
OpenAlexW4361267549

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.